رادار التجارب AI | ||
|---|---|---|
حالة التجربة السريرية NCT06150222 (Retro-COSMOS) لـ Cancer, Cervical، تكرار، نقيلة هي لم يبدأ القبول بعد. اطلعوا على جميع التفاصيل في عرض البطاقة الخاص برادار التجارب السريرية وأدوات اكتشاف الذكاء الاصطناعي. أو يمكنكم طرح أي سؤال هنا. | ||
تجربة واحدة تطابق معايير الفلتر
عرض البطاقة
Retrospective Cervical Cancer Oligo States (Recurrence, Metastasis) Multicentre Outcomes Study (Retro-COSMOS) ٣٥٠ دولية
تفاصيل التجربة السريرية متاحة بشكل أساسي باللغة الإنجليزية. ومع ذلك، يمكن لـ رادار التجارب AI مساعدتك؛ ما عليك سوى النقر على «وصف الدراسة» لعرض ومناقشة معلومات التجربة باللغة التي اخترتها.
التجربة السريرية NCT06150222 (Retro-COSMOS) هي دراسة رصدية لـCancer, Cervical، تكرار، نقيلة وهي لم يبدأ القبول بعد. من المقرر أن يبدأ التسجيل في ١٦ جمادى الأولى ١٤٤٥ هـ لتجنيد ٣٥٠ مشاركًا. يقودها Erasmus Medical Center، ومن المتوقع اكتمالها بحلول ٢٧ صفر ١٤٤٩ هـ. تم تحديث البيانات الأخيرة من ClinicalTrials.gov في ١٧ جمادى الأولى ١٤٤٥ هـ.
الملخص
This multi centric international retrospective study aims to register patients with oligo metastatic and oligo recurrent cervical cancer. The study will register patients in planned period with an aim to analyse clinical outcomes with or without use of radiation in this setting.
وصف مفصل
Detailed clinical protocol can be obtained by contacting the principal investigator.
العنوان الرسمي
Retrospective Cervical Cancer Oligo States (Recurrence, Metastasis) Multicentre Outcomes Study (Retro-COSMOS). An EMBRACE Collaborative Initiative in Recurrent and Metastatic Cervix Cancer.
الحالات الطبية
Cancer, Cervicalتكرارنقيلةمعرّفات دراسة أخرى
- Retro-COSMOS
- MEC-2022-0355/ TMC-IEC-900891
NCT معرّف
تاريخ البدء (فعلي)
2023-11-30
آخر تحديث مُنشور
2023-12-01
تاريخ الاكتمال (المقدر)
2027-07-31
عدد المشاركين المخطط لهم
٣٥٠
نوع الدراسة
رصدية
الحالة
لم يبدأ القبول بعد
الكلمات الرئيسية
Reirradiation
OligoRecurrence
Oligometastasis
OligoRecurrence
Oligometastasis
مجموعات/التدخلات
| مجموعة المشاركين/الذراع | التدخل/العلاج |
|---|---|
غ/م | Concurrent Chemoradiation, Systemic Chemotherapy other locally directed therapies (like surgery, ablation, etc.) The aim is to include all patients with (induced) oligo metastatic and oligo recurrent settings, irrespective of whether treated with concurrent chemoradiation, systemic chemotherapy, or with other locally directed therapies (like surgery, ablation, etc.) |
النتيجة الرئيسية
النتيجة الثانوية
| مقياس النتيجة | وصف القياس | الإطار الزمني |
|---|---|---|
3-year overall survival | To estimate overall survival of patients diagnosed with oligo-recurrent and (induced) oligo-metastatic cervix cancer. | From date of diagnosis of recurrence untill the date of death due to any cause or date of censoring at the last time the subject was known to be alive, whichever came first, assessed upto 3 years after initiation of the study |
| مقياس النتيجة | وصف القياس | الإطار الزمني |
|---|---|---|
3-year Infield progression free survival | To estimate infield progression-free survival and progression-free interval of patients diagnosed with oligo-recurrent and (induced) oligo-metastatic cervix cancer. | From date of first disease progression to date of subsequent progression or death from any cause, whichever came first, assessed upto 3 years after initiation of the study |
3- year Progression free survival | To estimate overall progression-free survival of patients diagnosed with oligo-recurrent and (induced) oligo-metastatic cervix cancer. | From date of first disease progression to subsequent disease progression or death from any cause, whichever came first, assessed upto 3 years after initiation of the study |
Dose response relationship of nodal and visceral progressions | Radiation Dose-Response Curve will be generated for mean time to nodal and visceral progressions at different dose level | From date of start of treatment of disease progression, assessed upto 3 years |
Dose response relationship within setting of re-irradiation (infield progressions) | Radiation Dose-Response Curve will be generated for mean time to infield progression at different dose level | From date of start of treatment of disease progression, assessed upto 3 years |
Moderate to severe adverse events within the (induced) oligo-metastatic and oligo-recurrent setting ( including toxicity with targeted agents like bevacuzimab and pembrolizumab) | Number or percent of participants with treatment-related moderate to severe adverse events as assessed by CTCAE v4.0 (If available) | From date of start of treatment of recurrence to end of study, assessed upto 3 years after initiation of the study |
Report on various risk groups within oligo-metastatic and oligo-recurrent setting | Clinical, pathological, and treatment-related factors of patients recorded during the sudy will be used to develop multivariable risk models to identify risk factors and define various risk groups within oligo-metastatic and oligo-recurrent setting | From date of recurrence to end of study, assessed upto 3 years after initiation of the study |
Nomogram which correlates risk groups with expected outcomes within the (induced) oligo-metastatic and oligo-recurrent setting | Nomogram will be developed which could estimate the probability of a expected outcomes (overall survival, infield progression free survival, overall progression free survival) based on the risk group the patient belongs to within oligo-metastatic and oligo-recurrent setting. | From date of recurrence to end of study, assessed upto 3 years after initiation of the study |
Tissue based biomarkers | Sponsor Institute will facilitate storage of biopsy tissue of patients within oligo-metastatic and oligo-recurrent setting included in this study. In future, these tissue samples will be used for translational reseach in this field. | From date of start of recurrence to end of study, assessed upto 3 years after initiation of the study |
مساعد المشاركة
معايير الأهلية
الأعمار المؤهلة للدراسة
بالغ, كبار السن
العمر الأدنى للدراسة
18 Years
الجنس المؤهل
أنثى
- Cervical cancer with (induced) oligo-metastatic and/or oligo-recurrent cervix cancer whether treated or not treated with radiation. These patients may have received previous treatment within or outside approved clinical trials/studies.
- Patients with poly-metastatic disease with good response to systemic chemotherapy and treated with radiation to recurrence or metastatic site.
- Patients treated with radical doses at the time of first diagnosis of oligo-metastasis/oligo-recurrence and present with further oligo-progression.
- Patients with oligo-metastasis or oligo-recurrence treated with other locally directed therapies (like surgery, ablation, etc.) are also permitted.
- Gynecological cancer other than cervical cancer
- Persistent Poly-metastatic disease post systemic treatment
- Receiving investigational new drugs at the time of relapse as part of other ongoing trials
- No clinical follow up after treatment
Erasmus Medical CenterTata Memorial Centreالجهة المسؤولة عن الدراسة
Prof. Dr. Remi A. Nout, المحقق الرئيسي, Head of Department of Radiation Oncology, Erasmus Medical Center
جهة اتصال مركزية للدراسة
جهة اتصال: Rene Vernhout, MSc, +31 107041341, [email protected]
لا توجد بيانات موقع.